Serviceeinschränkungen vom 12.-22.02.2026 - weitere Infos auf der UB-Homepage
  • A systematic review and Bayesi...

Treffer: A systematic review and Bayesian meta-analysis of the antibiotic treatment courses in AECOPD.

Title:
A systematic review and Bayesian meta-analysis of the antibiotic treatment courses in AECOPD.
Authors:
Yu H; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Clinical Medicine Department, First Clinical Medical Academy, Lanzhou University, Lanzhou, China., Lei T; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Clinical Medicine Department, First Clinical Medical Academy, Lanzhou University, Lanzhou, China., Su X; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Clinical Medicine Department, First Clinical Medical Academy, Lanzhou University, Lanzhou, China., Zhang L; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Clinical Medicine Department, First Clinical Medical Academy, Lanzhou University, Lanzhou, China., Feng Z; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Clinical Medicine Department, First Clinical Medical Academy, Lanzhou University, Lanzhou, China., Chen X; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Clinical Medicine Department, First Clinical Medical Academy, Lanzhou University, Lanzhou, China., Liu J; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.; Intensive Care Unit, Lanzhou University First Affiliated Hospital, Lanzhou, China.
Source:
Frontiers in pharmacology [Front Pharmacol] 2023 Jan 20; Vol. 14, pp. 1024807. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).
Publication Type:
Systematic Review; Journal Article
Language:
English
Journal Info:
Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Media]
References:
Lancet Respir Med. 2017 Jun;5(6):492-499. (PMID: 28483402)
Lancet. 2005 Feb 12-18;365(9459):579-87. (PMID: 15708101)
Int J Antimicrob Agents. 2001 Dec;18(6):503-12. (PMID: 11738336)
Chron Respir Dis. 2018 Aug;15(3):225-240. (PMID: 29232988)
Respir Med. 2000 Jan;94(1):18-27. (PMID: 10714475)
PLoS One. 2015 Apr 23;10(4):e0124374. (PMID: 25905726)
Chest. 2010 Nov;138(5):1108-15. (PMID: 20576731)
BMJ. 2010 May 18;340:c2096. (PMID: 20483949)
PLoS Med. 2020 Apr 3;17(4):e1003082. (PMID: 32243458)
Antimicrob Agents Chemother. 2005 Jan;49(1):153-60. (PMID: 15616290)
JAMA. 1995 Mar 22-29;273(12):957-60. (PMID: 7884956)
Curr Med Res Opin. 2005 Feb;21(2):245-54. (PMID: 15801995)
Lancet Respir Med. 2020 Jun;8(6):585-596. (PMID: 32526187)
Ann Intern Med. 2019 Aug 6;171(3):153-163. (PMID: 31284301)
PLoS One. 2021 May 20;16(5):e0251716. (PMID: 34015041)
J Chemother. 2000 Aug;12(4):314-25. (PMID: 10949981)
Am J Respir Crit Care Med. 2012 Oct 15;186(8):716-23. (PMID: 22923662)
Eur Respir J. 2012 Jul;40(1):17-27. (PMID: 22135277)
Pulm Pharmacol Ther. 2001;14(2):149-55. (PMID: 11273797)
J Antimicrob Chemother. 1988 Feb;21(2):225-32. (PMID: 3283093)
Scand J Prim Health Care. 1992 Mar;10(1):7-11. (PMID: 1589668)
Int J Chron Obstruct Pulmon Dis. 2015 Oct 22;10:2265-75. (PMID: 26543359)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Lancet. 2022 Feb 12;399(10325):629-655. (PMID: 35065702)
Lancet. 2001 Dec 15;358(9298):2020-5. (PMID: 11755608)
Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221099729. (PMID: 35657073)
Clin Microbiol Infect. 2007 Mar;13(3):284-90. (PMID: 17391383)
Ann Intern Med. 1987 Feb;106(2):196-204. (PMID: 3492164)
Thorax. 1995 Jul;50(7):758-63. (PMID: 7570411)
Antimicrob Resist Infect Control. 2019 Aug 13;8:137. (PMID: 31417673)
J Antimicrob Chemother. 1999 Oct;44(4):515-23. (PMID: 10588313)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
Pulm Pharmacol Ther. 2022 Feb;72:102111. (PMID: 35032637)
Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71. (PMID: 21680942)
Lancet Infect Dis. 2019 Jan;19(1):56-66. (PMID: 30409683)
Chest. 2004 Mar;125(3):953-64. (PMID: 15006954)
BMJ Open Respir Res. 2014 Dec 30;1(1):e000052. (PMID: 25562034)
Clin Drug Investig. 1998;15(1):13-20. (PMID: 18370461)
Contributed Indexing:
Keywords: Bayesian meta-analysis; acute exacerbation; antibiotics; chronic obstructive pulmonary disease; treatment course
Entry Date(s):
Date Created: 20230206 Latest Revision: 20230207
Update Code:
20250114
PubMed Central ID:
PMC9895851
DOI:
10.3389/fphar.2023.1024807
PMID:
36744244
Database:
MEDLINE

Weitere Informationen

Background: No consensus exists on the antibiotic treatment course for patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Former studies indicate that shorter courses might have the same efficacy with fewer adverse events, which is inconsistent with guidelines and general practice. Existing evidence allows us to conduct a systematic review and Bayesian analysis on this topic. Methods: Four databases were searched from their inception to January 5, 2023. All statistical estimations were performed using R. " Gemtc " was the core package of analysis. CINeMA was used to assess the grade of confidence of the results. Results: Fourteen studies were included in the Bayesian meta-analysis. No difference in the clinical success rate of antibiotic treatment was observed from a super short course (1-3 days) to a long course (≥10 days). Considering the adverse events, the short course (4-6 days) might be the safest. The majority of results were of high or moderate confidence grade. Conclusion: Short course might cause the fewest adverse events. The clinical efficacy of antibiotics might not depend on the course length. Undeniably, more systematic explorations are warranted to investigate the clinical application of a shorter course of antibiotic treatment.
(Copyright © 2023 Yu, Lei, Su, Zhang, Feng, Chen and Liu.)

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.